2
项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的临床试验A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins
RATIONALE: Vaccines made from human papillomavirus may make the body build an immune response to and kill cervical cancer cells. Combining vaccine therapy with surgery may be a more effective treatment for cervical cancer.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with surgery works in treating patients with early cervical cancer.
VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER
RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients who have advanced or recurrent cancer of the cervix, vagina, penis, anus, esophagus, or head and neck.
100 项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的临床结果
100 项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的转化医学
100 项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的专利(医药)
100 项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的药物交易